全球生产总值
抗血栓
血小板
医学
血小板膜糖蛋白
血小板活化
血栓形成
冲程(发动机)
药理学
免疫学
内科学
机械工程
工程类
作者
Alexandre Slater,Sophia Khattak,Mark R. Thomas
出处
期刊:European Heart Journal - Cardiovascular Pharmacotherapy
[Oxford University Press]
日期:2024-03-07
标识
DOI:10.1093/ehjcvp/pvae018
摘要
Glycoprotein (GP) VI plays a major role in thrombosis but not haemostasis, making it a promising antithrombotic target. The primary role of GPVI on the surface of platelets is a signalling receptor for collagen, which is one of the most potent thrombotic sub-endothelial components that is exposed by atherosclerotic plaque rupture. Inhibition of GPVI has therefore been investigated as a strategy for treatment and prevention of atherothrombosis, such as during stroke and acute coronary syndromes. A range of specific GPVI inhibitors have been characterised and 2 of these inhibitors, glenzocimab and revacept, have completed phase II clinical trials in ischemic stroke. In this review, we summarise mechanisms of GPVI activation and the latest progress of clinically tested GPVI inhibitors, including their mechanisms of action. By focussing on what is known about GPVI activation, we also discuss whether alternate strategies could also be used to target GPVI.
科研通智能强力驱动
Strongly Powered by AbleSci AI